Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer.
A critical role is revealed for MMGT1 in shaping the TNBC immune microenvironment and targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes, suggesting that targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes.